Daily Cosmetic Research Analysis
Three high-impact studies span aesthetic surgery, dermal anti-glycation science, and excipient safety. A randomized clinical study supports adding botulinum toxin A to superficial radiotherapy after chest keloid excision. A multifunctional Zn-based nanoparticle targeting dual RAGE pathways mitigates skin glycation damage in preclinical models, while formulation-dependent nephrotoxicity of propyl gallate underscores critical safety considerations across pharmaceuticals and cosmetics.
Summary
Three high-impact studies span aesthetic surgery, dermal anti-glycation science, and excipient safety. A randomized clinical study supports adding botulinum toxin A to superficial radiotherapy after chest keloid excision. A multifunctional Zn-based nanoparticle targeting dual RAGE pathways mitigates skin glycation damage in preclinical models, while formulation-dependent nephrotoxicity of propyl gallate underscores critical safety considerations across pharmaceuticals and cosmetics.
Research Themes
- Adjunctive therapies to reduce keloid recurrence and improve cosmetic outcomes
- Dual-pathway anti-glycation nanotherapies for skin health
- Formulation-dependent excipient toxicity and cross-species safety
Selected Articles
1. Clinical Efficacy Analysis of Botulinum Toxin Type A Combined with Superficial Radiotherapy after Chest Keloid Surgery.
In a randomized comparison of 60 patients after chest keloid excision, immediate botulinum toxin A injection combined with superficial radiotherapy improved overall response and patient satisfaction and reduced Vancouver Scar Scale scores at 6 months versus radiotherapy alone. Findings support BTX-A as an adjunct to standard post-excisional radiotherapy for chest keloids.
Impact: This trial provides prospective randomized evidence for an accessible adjunct that can reduce recurrence-related morbidity and improve cosmetic outcomes in a challenging keloid population.
Clinical Implications: Consider intraoperative or immediate postoperative BTX-A injection with superficial radiotherapy after chest keloid excision to improve scar quality and satisfaction; longer follow-up and broader anatomical validation are needed before guideline changes.
Key Findings
- Randomized 60-patient study comparing BTX-A plus superficial radiotherapy vs radiotherapy alone after chest keloid excision.
- Adjunctive BTX-A significantly improved total effective rate and patient satisfaction at 6 months (P<0.05).
- Vancouver Scar Scale scores were significantly lower with combination therapy; recurrence rate was reported lower qualitatively.
Methodological Strengths
- Randomized allocation with a defined comparator and standardized post-excisional care.
- Use of validated scar outcome metric (Vancouver Scar Scale) with 6-month follow-up.
Limitations
- Single-center, small sample size and short follow-up (6 months).
- Blinding and detailed adverse event profiles were not reported; outcomes limited to chest keloids.
Future Directions: Larger multi-center, blinded RCTs with longer follow-up across anatomical sites to confirm recurrence reduction, optimize dosing/timing, and assess safety.
BACKGROUND: There are many treatments for keloid. In recent years, botulinum toxin type A(BTX-A)has been proposed to treat keloid. The purpose of our study was to observe the clinical effect of BTX-A combined with superficial radiotherapy after chest keloid surgery. METHODS: 60 patients with medium and large chest keloid treated from October 2021 to October 2023 were selected and randomly divided into group A and group B, with 30 cases in each group. Keloid resection was performed in both groups first, group A was treated with BTX-A combined with superficial radiotherapy, group B only received early superficial radiotherapy after surgery, and the therapeutic effect of the two groups was compared. RESULTS: After 6 months follow-up observation, the total effective rate and satisfaction of group A were higher than those of group B, and the Vancouver scar scale(VSS) score of group A was lower than that of group B, the difference was statistically significant (P < 0.05). CONCLUSIONS: We concluded that immediate injection of BTX-A combined with superficial radiotherapy after chest keloid surgery was superior to simple superficial radiotherapy after surgery, with higher patient satisfaction and lower recurrence rate, which was worthy of clinical application. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
2. Zn-Based Multi-Active Framework Nanoparticles TSA-CAN-Zn Inhibit Skin Glycation via Dual Blockade of HMGB1/RAGE and AGEs/RAGE Pathways.
A Zn-based multi-active nanoparticle incorporating theasinensin A and L-carnosine concurrently inhibited HMGB1/RAGE binding and AGEs/RAGE signaling. It reduced oxidative stress, apoptosis, and inflammatory mediators in keratinocytes, enhanced lysosomal AGEs clearance, and ameliorated skin glycation damage in mice, with single-cell RNA-seq mapping cell-type-specific effects.
Impact: Demonstrates a dual-pathway anti-glycation strategy with multi-modal validation (cellular, in vivo, and single-cell transcriptomics), offering a mechanistically grounded candidate for dermal anti-glycation interventions.
Clinical Implications: Supports development of cosmeceutical or therapeutic formulations targeting glycation-related skin aging and inflammation; requires human pharmacokinetic, safety, and efficacy trials.
Key Findings
- Theasinensin A identified as an HMGB1–RAGE interaction inhibitor; L-carnosine included to suppress AGEs formation.
- TSA-CAN-Zn scavenged radicals, inhibited AGEs formation, reduced ROS, apoptosis, and inflammatory cytokines in HaCaT cells, and enhanced lysosomal degradation of AGEs.
- In a mouse skin glycation model, TSA-CAN-Zn mitigated tissue damage; single-cell RNA-seq highlighted effects on epidermal basal cells and inflammatory macrophages and modulation of RAGE downstream pathways.
Methodological Strengths
- Integrated in vitro cellular assays, in vivo mouse model, and single-cell RNA sequencing.
- Rational design with dual-target mechanism (HMGB1/RAGE and AGEs/RAGE) grounded in molecular docking.
Limitations
- Preclinical study without human data on safety, penetration, or clinical efficacy.
- Long-term biocompatibility and off-target effects of Zn-based frameworks remain to be established.
Future Directions: Define dermal pharmacokinetics and safety, optimize formulation for skin delivery, and progress to early-phase human trials in glycation-associated dermatoses or photoaging.
Receptor for advanced glycation end products (RAGE) plays an important role in skin glycation damage. High-mobility group 1B protein (HMGB1) and advanced glycation end products (AGEs) are key RAGE ligands. Simultaneous inhibition of HMGB1/RAGE and AGEs/RAGE pathways maybe an effective strategy to alleviate glycation induced skin damage. In this work, Theasinensin A (TSA) is identified as the active molecule inhibiting HMGB1-RAGE interaction through molecular docking. To simultaneously suppress HMGB1/RAGE and AGEs/RAGE pathways, Zn-based multi-active framework nanoparticles TSA-CAN-Zn are designed, which contain TSA and the active molecule L-carnosine (CAN) that inhibits AGEs production. In vitro studies demonstrated that TSA-CAN-Zn have radical scavenging activity and AGEs formation inhibition activity. TSA-CAN-Zn can not only inhibit ROS accumulation, cell apoptosis, and inflammatory factors production induced by glycation in HaCaT cells but also enhanced the lysosomal degradation of AGEs. TSA-CAN-Zn also mitigated the damage caused by glycation in mouse skin glycation model. Single-cell RNA sequencing results revealed the impact of TSA-CAN-Zn on different cell types of skin tissue, especially the basal cells of the epidermal layer and inflammation-related macrophages. And pathway analysis revealed that TSA-CAN-Zn mainly influences the downstream pathways of RAGE. Collectively, TSA-CAN-Zn is a promising therapeutic candidate for ameliorating glycation-induced skin damage.
3. Investigations of Enteric-Coated Tablet Propyl Gallate-Induced Nephrotoxicity in Beagles as well as Human and Dog Renal Proximal Tubule Epithelial Cells.
Enteric-coated propyl gallate caused nephrotoxicity in beagles, linked to species-specific cellular responses: dog RPTECs were more sensitive than human cells and lacked a robust glutathione elevation. Non-enteric PG capsules did not induce renal toxicity in dogs, implicating absorption route. A 10-plex LC-MS/MS assay for PG and metabolites supports translational PK and safety studies.
Impact: Widely used as an antioxidant in food and cosmetics, PG’s formulation-dependent nephrotoxicity and species differences raise critical safety and regulatory considerations; the analytical platform enables rigorous PK/metabolism assessment.
Clinical Implications: For products containing PG, avoid exposure scenarios that mimic enteric bolus delivery; reassess formulation choices and monitor renal safety where relevant, while leveraging LC-MS/MS analytics in translational studies.
Key Findings
- Enteric-coated PG induced nephrotoxicity in beagles; non-enteric capsule PG did not, indicating absorption-route effects.
- Dog RPTECs showed greater cytotoxicity to PG than human RPTECs, with human cells mounting higher glutathione responses.
- Developed a sensitive 10-plex LC-MS/MS method to quantify PG and phase I/II metabolites for preclinical and clinical support (NCT03362593).
Methodological Strengths
- Cross-species cellular toxicology combined with in vivo formulation comparison.
- Advanced multiplex LC-MS/MS platform enabling comprehensive PK/metabolite profiling.
Limitations
- Mechanistic attribution remains partly inferential; glutathione response may not fully explain toxicity.
- Translatability from beagle to human risk requires cautious interpretation and clinical confirmation.
Future Directions: Define intestinal exposure kinetics under enteric conditions, assess renal biomarkers in human PG exposures, and refine formulations to minimize renal risk.
During nonclinical development of an oral formulation for a glucagon-like peptide-1 (GLP-1) receptor agonist, MEDI7219, toxicology studies revealed that propyl gallate (PG), when administered in enteric-coated (EC) tablets, led to nephrotoxicity in beagles. While PG has been widely used in food and cosmetics as an antioxidant, understanding of its toxicology, metabolism, and pharmacokinetics has been rarely discussed. To elucidate the nephrotoxicity observed after administration of PG in an EC tablet formulation, we employed dog and human renal proximal tubule epithelial cells (RPTECs). We observed greater cytotoxicity to PG in dog RPTECs compared to human cells and greater increases in response to PG treatment of glutathione in human cells compared to dog cells. Glutathione elevation is a common response to detoxify xenobiotics, especially ones that produce free radicals such as PG. We hypothesize that glutathione in human RPTECs was elevated to detoxify PG, but not in dog RPTECs, leading to greater cytotoxicity for dog RPTECs. However, a subsequent study in dogs demonstrated that the oral administration of PG in a non-EC capsule did not result in renal toxicity, suggesting the physiological response to PG is modulated by the mode of absorption and a blunted glutathione response may not completely explain the PG-related renal toxicity observed in dogs. Furthermore, to characterize the pharmacokinetics and metabolism of PG we developed a 10-plex, highly sensitive and robust LC-MS/MS-based quantification method for PG and its phase-I and phase-II metabolites. The methods were employed to support preclinical dog studies and clinical study (NCT03362593).